NCT05970640 - A Study to Test How Well Different Doses of BI 3006337 Are Tolerated by People With Overweight or Obesity and With Fatty Liver Disease | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 14, 2023

Primary Completion Date

October 31, 2024

Study Completion Date

November 7, 2024

Conditions

Non-alcoholic Fatty Liver DiseaseObesity

Interventions

DRUG

BI 3006337

DRUG

Placebo matching BI 3006337

Trial Locations (12)

iResearch Atlanta, Decatur

Accel Research Sites-Deland-67606, DeLand

Floridian Clinical Research-Miami Lakes-68368, Miami Lakes

AMR Knoxville, Knoxville

Centricity Research-Columbus-68879, Columbus

The Liver Institute at Methodist Dallas, Dallas

American Research Corporation at the Texas Liver Institute, San Antonio

Endeavor Clinical Trials, San Antonio

Velocity Clinical Research-West Jordan-69043, West Jordan

Catalina Research Institute, LLC-Montclair-49051, Montclair

Velocity Clinical Research-Chula Vista-67286, Chula Vista

Velocity Clinical Research-La Mesa-69117, La Mesa